Sanofi Buys TargeGen And Its Lead Myelofibrosis Drug For $75 Million Upfront

It's another earn-out based exit for venture capital, but TargeGen's backers could realize more than five times their initial investment if all milestones are achieved.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet